Corrigendum to: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)

This is a corrigendum to: Marc Humbert, Gabor Kovacs, Marius M Hoeper, Roberto Badagliacca, Rolf M F Berger, Margarita Brida, Jørn Carlsen, Andrew J S Coats, Pilar Escribano-Subias, Pisana Ferrari, Diogenes S Ferreira, Hossein Ardeschir Ghofrani, George Giannakoulas, David G Kiely, Eckhard Mayer, Gergely Meszaros, Blin Nagavci, Karen M Olsson, Joanna Pepke-Zaba, Jennifer K Quint, Göran Rådegran, Gerald Simonneau, Olivier Sitbon, Thomy Tonia, Mark Toshner, Jean Luc Vachiery, Anton Vonk Noordegraaf, Marion Delcroix, Stephan Rosenkranz, ESC/ERS Scientific Document Group, 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)., European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3618–3731, https://doi.org/10.1093/eurheartj/ehac237 Since the originally published version of these guidelines a number of changes have been made to the references throughout the paper: • In the section “5.1.3. Chest radiography” reference 26 has been added. • In the first sentence of the section “6.2.3. Haemodynamics” reference 246 has been removed. • In the first sentence of paragraph 3 under “6.2.7. Comprehensive prognostic evaluation, risk assessment, and treatment goals” reference 274 has been replaced by reference 292. • In “Recommendation Table 9” reference 430 has replaced reference 303 under “Initial combination therapy with other ERAs and PDE5is should be considered”. • In “Recommendation Table 10” reference 419a has replaced reference 419 under “The addition of bosentan to sildenafil is not recommended to reduce the risk of morbidity/mortality events”. • In sentence 3 under “8.2.1. Diagnosis and control of the underlying left heart disease” reference 293 has been removed. • At the end of the first sentence of paragraph 5 under “8.1. Definition, prognosis, and pathophysiology” reference 655 has been added. • In “Recommendation Table 24a” reference 803 has been removed from “Off-label use of drugs approved for PAH may be considered in symptomatic patients who have inoperable CTEPH”. A number of changes have also been made to the references in the supplementary data file: • In table S12, under “ASSESSMENT”, “Desirable effects”, and “Research evidence” reference 224 has been replaced by reference 209. Reference 223 has been removed. • In table S12, under “ASSESSMENT”, “Undesirable effects”, and “Research evidence” reference 223 has been removed. • In table S14, under “ASESSMENT”, “Acceptability”, and “Research evidence” reference 247 has been replaced with reference 108. Reference 107 has been added. • In table S15 under “ASSESSMENT”, “Problem”, and “Research evidence” references 247 and 250 have been replaced by references 107 and 108. • In table S15 under “ASSESSMENT”, “Desirable effects”, and “Research evidence” references 253, 254, and 255 have been replaced with references 143, 145, and 146. • References 203 to 263 have had the DOI removed. • References 224, 247, 250, 253, 254, and 255 have been removed as duplicates. These errors have been corrected online.